Literature DB >> 8956997

Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins.

G Hateboer1, R M Kerkhoven, A Shvarts, R Bernards, R L Beijersbergen.   

Abstract

E2F transcription factors are key regulators of transcription during the cell cycle. E2F activity is regulated at the level of transcription and DNA binding and by complex formation with the retinoblastoma pocket protein family. We show here that free E2F-1 and E2F-4 transcription factors are unstable and that their degradation is mediated by the ubiquitin-proteasome pathway. Both E2F-1 and E2F-4 are rendered unstable by an epitope in the carboxyl terminus of the proteins, in close proximity to their pocket protein interaction surface. We show that binding of E2F-1 to pRb or E2F-4 to p107 or p130 protects E2Fs from degradation, causing the complexes to be stable. The increased stability of E2F-4 pocket protein complexes may contribute to the maintenance of active transcriptional repression in quiescent cells. Surprisingly, adenovirus transforming proteins, which release pocket protein-E2F complexes, also inhibit breakdown of free E2F. These data reveal an additional level of regulation of E2F transcription factors by targeted proteolysis, which is inhibited by pocket protein binding and adenovirus early region 1 transforming proteins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8956997     DOI: 10.1101/gad.10.23.2960

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  61 in total

1.  p19ARF targets certain E2F species for degradation.

Authors:  F Martelli; T Hamilton; D P Silver; N E Sharpless; N Bardeesy; M Rokas; R A DePinho; D M Livingston; S R Grossman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 2.  Molecular interaction map of the mammalian cell cycle control and DNA repair systems.

Authors:  K W Kohn
Journal:  Mol Biol Cell       Date:  1999-08       Impact factor: 4.138

3.  c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.

Authors:  M A Gregory; S R Hann
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

4.  Regulation of endogenous E2F1 stability by the retinoblastoma family proteins.

Authors:  F Martelli; D M Livingston
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

5.  Cumulative effect of phosphorylation of pRB on regulation of E2F activity.

Authors:  V D Brown; R A Phillips; B L Gallie
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

6.  Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation.

Authors:  W C Lin; F T Lin; J R Nevins
Journal:  Genes Dev       Date:  2001-07-15       Impact factor: 11.361

7.  Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes.

Authors:  A M Helt; D A Galloway
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

8.  Induction of S-phase entry by E2F transcription factors depends on their nuclear localization.

Authors:  H Müller; M C Moroni; E Vigo; B O Petersen; J Bartek; K Helin
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

9.  Clastosome: a subtype of nuclear body enriched in 19S and 20S proteasomes, ubiquitin, and protein substrates of proteasome.

Authors:  Miguel Lafarga; Maria Teresa Berciano; Emma Pena; Isabel Mayo; Jose G Castaño; Dirk Bohmann; João Pedro Rodrigues; João Paulo Tavanez; Maria Carmo-Fonseca
Journal:  Mol Biol Cell       Date:  2002-08       Impact factor: 4.138

10.  Increased levels and activity of E2F1 transcription factor in myelodysplastic bone marrow.

Authors:  Gurveen Saberwal; Steven Lucas; Imke Janssen; Avnish Deobhakta; Wen-Yang Hu; Naomi Galili; Azra Raza; Suneel D Mundle
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.